Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

843.60 +5.40 (+0.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,087,287
Open 844.61
Bid (Size) 836.10 (1)
Ask (Size) 852.00 (1)
Prev. Close 838.20
Today's Range 837.88 - 862.00
52wk Range 783.57 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily

Performance

YTD
-6.78%
-6.78%
1 Month
-16.85%
-16.85%
3 Month
-21.25%
-21.25%
6 Month
-12.00%
-12.00%
1 Year
+3.27%
+3.27%

More News

Read More
Regeneron Earnings Top Views For Biotech Giant
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
Via Benzinga
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Regeneron Reports Third Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
What the Options Market Tells Us About Regeneron Pharmaceuticals
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Via Benzinga
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Via Talk Markets
Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Via MarketBeat
Topics ETFs Earnings
Exposures Financial
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.